000198630 000__ 01448fam\a2200337\a\4500
000198630 001__ 198630
000198630 005__ 20220217103908.0
000198630 008__ 980107s1997\\\\dcu\\\\\\\\\\f000\0\eng\d
000198630 020__ $$a0160557593 :$$c$4.25
000198630 035__ $$a(OCoLC)38166389
000198630 035__ $$9(IS)TVZ9085
000198630 035__ $$9AAW8529SI
000198630 035__ $$a198630
000198630 040__ $$aGPO$$cGPO
000198630 043__ $$an-us---
000198630 049__ $$aISUW
000198630 074__ $$a1019-A-01
000198630 0860_ $$aY 4.C 73/8:105-44
000198630 088__ $$aSerial no. 105-44 (United States. Congress. House. Committee on   Commerce)
000198630 1101_ $$aUnited States.$$bCongress.$$bHouse.$$bCommittee on Commerce.$$bSubcommittee on Oversight and Investigations.
000198630 24510 $$aAdequacy of access to investigative drugs for seriously ill         patients :$$bhearing before the Subcommittee on Oversight and Investigations   of the Committee on Commerce, House of Representatives, One Hundred Fifth       Congress, first session, September 23, 1997.
000198630 260__ $$aWashington :$$bU.S. G.P.O. :$$bFor sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office,$$c1997.
000198630 300__ $$aiii, 78 p. ;$$c24 cm.
000198630 500__ $$aDistributed to some depository libraries in microfiche.
000198630 500__ $$aShipping list no.: 98-0082-P.
000198630 500__ $$a"Serial no. 105-44."
000198630 650_0 $$aDrugs$$zUnited States$$xTesting.
000198630 650_0 $$aClinical trials$$zUnited States.
000198630 650_0 $$aHuman experimentation in medicine$$zUnited States.
000198630 650_0 $$aMedical ethics$$zUnited States.
000198630 85230 $$bdfich$$hY 4.C 73/8:$$i105-44
000198630 909CO $$ooai:library.usi.edu:198630$$pGLOBAL_SET
000198630 948__ $$ac:jb
000198630 980__ $$aBIB
000198630 980__ $$aGOV RESOURCE